Highest incidence of major adverse cardiovascular events seen in those with incident fragility fracture
FRIDAY, Sept. 9, 2022 (HealthDay News) — Individuals with high fracture risk, especially those with previous fracture, have an increased risk for cardiovascular disease (CVD) events, according to a study published online July 11 in the Journal of Bone and Mineral Research.
Marta Pineda-MoncusÃ, Ph.D., from the University of Oxford in the United Kingdom, and colleagues estimated the incidence rate of CVD events at one year among three cohorts of patients with high fracture risk. Major adverse cardiovascular events (MACE) were identified among patients aged 50 years or older who were recently diagnosed with osteoporosis (OST; 65,295 participants), who experienced incident fragility fracture (IFX; 67,065 patients), and who were starting oral bisphosphonates (OBP; 145,959 participants).
The researchers found that about 1.90, 4.39, and 2.38 percent of the participants in the OST, IFX, and OBP cohorts, respectively, experienced MACE events. MACE incidence rates (cases/1,000 person-years) were 19.63, 52.64, and 26.26 in the OST, IFX, and OBP cohorts, respectively. Good discrimination (≥70 percent) and internal validity were seen for models using a set of general, CVD, and fracture candidates; these models generally outperformed those using only CVD risk factors of the general population. Sex, age, smoking, alcohol, atrial fibrillation, antihypertensive medication, previous myocardial infarction/stroke, established CVD, glomerular filtration rate, systolic blood pressure, cholesterol levels, and number of concomitant medicines were the main risk factors common to all MACE models.
“Efforts in predicting the study events outline the differences between general and the osteoporotic/fracture risk population,” the authors write. “The resulting algorithms include risk factors specific to the study population as well as more generic features that can be found easily in primary care data.”
Several authors disclosed financial ties to the pharmaceutical industry.
Copyright © 2022 HealthDay. All rights reserved.
